Fiche publication
Date publication
mars 2026
Journal
Diabetes, obesity & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr QUILLIOT Didier
Tous les auteurs :
Bel Lassen P, Jacobi D, Brindisi MC, Bonnet JB, Subtil F, Bin S, Abad F, Poitou C, Segrestin B, Ledoux S, Gaborit B, Aron-Wisnewsky J, Carette C, Zerguine M, Gatta-Cherifi B, Quilliot D, Montastier E, Avignon A, Mosbah H, Czernichow S, Disse E
Lien Pubmed
Résumé
Although semaglutide 2.4 mg has demonstrated significant weight loss efficacy in clinical trials, real-world data, particularly with regard to clinically complex and underrepresented populations, remain limited.
Mots clés
GLP‐1 analogue, antiobesity drug, cohort study, obesity care, real‐world evidence, semaglutide
Référence
Diabetes Obes Metab. 2026 03 26;:
